Comparative Pharmacology
Head-to-head clinical analysis: DOXY 200 versus MONODOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 200 versus MONODOX.
DOXY 200 vs MONODOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking the attachment of aminoacyl-tRNA to the mRNA-ribosome complex.
200 mg orally once daily or 100 mg orally every 12 hours.
100 mg orally or IV every 12 hours on day 1, then 100 mg orally or IV every 24 hours; for severe infections, 100 mg every 12 hours.
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
Terminal elimination half-life: 14-22 hours (mean ~18 hours) in adults; prolonged up to 24-48 hours in renal impairment; no dose adjustment in mild-moderate renal impairment but caution in severe (CrCl <30 mL/min).
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Renal: ~40% (glomerular filtration, tubular secretion); biliary: ~20-60% (enterohepatic circulation); fecal: ~30% (unabsorbed or excreted in bile).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic